Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as melphalan, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Sorafenib may also make tumor cells more
sensitive to melphalan. Giving sorafenib together with an isolated limb infusion of melphalan
may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib when
given together with an isolated limb infusion of melphalan in treating patients with stage
III melanoma of the arm or leg.